Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Cancer Institute CRADA

Executive Summary

NCI is seeking pharmaceutical/biotech company to enter into a Cooperative Research & Development Agreement for the anti-Tac(Fv)- PE38 single chain immunotoxin as a therapy for leukemias or lymphomas, NCI announces in Oct. 7 Federal Register. The recombinant immunotoxin fuses the combining site of the anti-Tac monoclonal antibody, which reacts with human interleukin-2 receptors found in many types of leukemias, lymphomas and activated human T cells, to the recombinant form of Pseudomonas exotoxin "in which the cell binding domain of the toxin has been removed," the notice states. Anti-Tac(Fv)-PE38 preclinicals indicate that the toxin can produce complete remission of human tumors in mice without significant toxicities. Anti-Tac(Fv)-PE38 also has been shown to be "very active in killing activated human monocytes and may be useful in treating autoimmune diseases," NCI says. Statements of interest in the CRADA are due on or before Jan. 5, 1994. Questions to NCI's Ira Pastan, MD: (301) 496-4797; FAX (301) 402-1344.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel